Although surgery remains the standard of care for squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), for patients who are poor surgical candidates, have multiple lesions, or defer surgery, alternative treatments are limited. Recent evidence suggests that the human papillomavirus (HPV) is involved in the pathogenesis of SCC.\textsuperscript{1-3} The 9-valent HPV vaccine is approved by the US Food and Drug Administration to prevent genital warts and anogenital cancer caused by HPV infection. We previously reported that receiving the intramuscular HPV vaccine reduced the development of new SCCs in immunocompetent patients without known HPV infection.\textsuperscript{4} These cases and the fact that other types of vaccines delivered directly into tumors elicit immune responses capable of eradicating tumor cells led to our using a combination of systemic and intratumoral HPV vaccine for a patient with inoperable SCCs.

An immunocompetent woman in her 90s presented to a university-based outpatient dermatology clinic with numerous large, nontender, exophytic tumors on her right leg (Figure 1A). Histopathologic examination demonstrated tumor islands of basaloid cells with central comedolike necrosis within a fibrotic dermis, extending from the undersurface of the epidermis (Figure 2A and Figure 3A). Immunohistochemical analysis results were positive for epithelial membrane antigen, negative for Ber-EP4, and strongly positive for p16 (Figure 2B-D), confirming the diagnosis of basloid SCC, an aggressive SCC with a high recurrence rate after Mohs micrographic surgery and a propensity to metastasize.\textsuperscript{5} Posi-
tron emission tomography–computed tomography findings showed no abnormalities, eliminating the possibility that these tumors represented metastatic basaloid SCC from a distant, noncutaneous site. Mohs surgery was performed on the largest tumor, but considering the patient’s advanced age and extensive tumor burden, additional surgery and radiotherapy were considered to be unfeasible. After the patient declined systemic chemotherapy, she was treated off-label with the 9-valent HPV vaccine delivered systemically and then intratumorally to the largest tumors.

Methods

With the oral informed consent of the patient and her son, the patient was treated with the 9-valent HPV vaccine (Gardasil-9; Merck & Co Inc) from March 17, 2016, through February 27, 2017, and was followed up through May 21, 2018. She was initially treated with 2 doses of intramuscular HPV vaccine administered 6 weeks apart. Three weeks after the second intramuscular dose, 3 of the largest tumors were treated intratumorally with 9-valent HPV vaccine (0.5 mL) diluted with sterile saline (2.5 mL) (Figure 1A) after the tumors had been anesthetized with lidocaine, 1%, with epinephrine (1:100,000). Three additional similar doses of the HPV vaccine were administered intratumorally during the ensuing 8 months (Figure 1B), leading to complete resolution (Figure 1C). No additional treatments were used.

Results

Clinical improvement was observed 2 weeks after the second intratumoral dose of the 9-valent HPV vaccine with reduction in tumor size and number. Eleven months after the first intratumoral dose, there was no clinical or histologic evidence of residual SCC. On examination, there were small violaceous scars and 1 small, pink, scaly, minimally elevated papule on her right leg at sites corresponding to previous large tumors (Figure 1A-C). Histopathologic analysis of the pink, scaly papule was performed, the results of which demonstrated mild cellular atypia of basal keratinocytes with hyperkeratosis (Figure 3). The only adverse effect was mild pain within some of the tumors on the day of intratumoral vaccine administration. No systemic adverse effects were reported. At the patient’s most recent follow-up visit, 24 months after the first intratumoral administration of the HPV vaccine, there was no clinical evidence of SCC recurrence.

Discussion

We report the first case, to our knowledge, of complete regression of multiple cutaneous SCCs after combined systemic and intratumoral delivery of the 9-valent HPV vaccine. Clinical improvement was observed 2 weeks after the second intratumoral dose of the 9-valent HPV vaccine, with reduction in tumor size and number. Eleven months after the first intratumoral dose, there was no clinical or histologic evidence of residual SCC. On examination, there were small violaceous scars and 1 small, pink, scaly, minimally elevated papule on her right leg at sites corresponding to previous large tumors (Figure 1A-C). Histopathologic analysis of the pink, scaly papule was performed, the results of which demonstrated mild cellular atypia of basal keratinocytes with hyperkeratosis (Figure 3). The only adverse effect was mild pain within some of the tumors on the day of intratumoral vaccine administration. No systemic adverse effects were reported. At the patient’s most recent follow-up visit, 24 months after the first intratumoral administration of the HPV vaccine, there was no clinical evidence of SCC recurrence.
temic and intratumoral delivery of the 9-valent HPV vaccine. The marked regression of numerous SCCs after initiation of the intratumoral injections eliminated the need for additional treatment. Tumors not directly injected with the vaccine also regressed, possibly by local dispersion of the vaccine or its effects on immune-mediated mechanisms. These findings suggest that the 9-valent HPV vaccine can provide a therapeutic option for inoperable cutaneous SCCs, in addition to its approved use to prevent anogenital HPV infection.

The development of therapeutic vaccines has created a new era for cancer treatments. In 2015, the US Food and Drug Administration approved the first oncolytic virus vaccine for the treatment of inoperable metastatic melanoma,
talimogene laherparepvec, an engineered herpes virus injected directly into tumors.\(^6\) An attenuated poliovirus oncolytic vaccine is injected directly into glioblastoma multiforme.\(^7\) Although associated with an unfavorable adverse effect profile, the BCG vaccine has been used intratumorally for metastatic melanoma and intravesically for bladder carcinoma.\(^8\)

Human papillomavirus is a highly prevalent virus that colonizes skin and mucosa. More than 200 HPV types have been identified, including high-risk carcinogenic types with a well-established role in the development of anogenital and oropharyngeal carcinomas. It is estimated that approximately 5% of human malignant tumors may be associated with HPV.\(^9\) Numerous studies\(^1,3,10,11\) have described the association between the β-genus of HPV (β-HPV) and the development of keratinocyte carcinomas. The β-HPV types 5, 8, 15, 17, 20, 24, 36, and 38 are associated with an increased risk of developing cutaneous SCC,\(^2\) and the risk is higher in individuals who are seropositive for multiple β-HPV subtypes.\(^10\) The β-HPV DNA, mainly subtypes 5 and 8, can be found in 90% of keratinocyte carcinomas in immunocompromised patients and 50% of keratinocyte carcinomas in immunocompetent patients.\(^11\)

Several mechanisms have been proposed to explain the role of HPV in the development of keratinocyte carcinomas, including the expression of oncoproteins E6 and E7, which can deregulate gene expression, stimulate keratinocyte proliferation, and immortalize keratinocytes, creating a favorable environment for viral replication, particularly when UV damage is present.\(^2,12\) The 9-valent HPV vaccine treats a variety of mucocutaneous conditions, including recalcitrant cutaneous warts and oral papillomas. We found that vaccination against HPV can also prevent the development of SCCs and BCCs in immunocompetent individuals.\(^4\)

### Conclusions

It is not known what part, if any, the systemic doses of the vaccine played in the therapeutic benefit that we observed after the intratumoral injections in the patient. The prophylactic role of HPV vaccination is well understood; however, the mechanisms of its therapeutic efficacy in cutaneous malignant tumors are not yet clear. The potent therapeutic benefit may reflect a combination of immunologic, antiviral, and antitumor effects of 9-valent HPV vaccine.